Full Press Release Details
WALTHAM, Mass., March 04, 2026 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company focused on the development and commercialization of innovative medicines that meet significant unmet medical needs, today announced its participation in the following upcoming investor conferences:
Leerink Partners 2026 Global Healthcare ConferenceLocation: Miami, FLPresentation: Tuesday, March 10 at 4:20 p.m. ET1x1 Meetings: Tuesday, March 10
To access the live webcast of the Leerink presentation, please visit the Events and Presentations page within the Ardelyx website atir.ardelyx.com. A replay of the panel presentation will be available on the Ardelyx website for 30 days following the event.
Jefferies 2026 Biotech on the Beach SummitLocation: Miami, FL1x1 Meetings: Wednesday, March 11
About Ardelyx, Inc.Ardelyx is a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative medicines that meet significant unmet medical needs. Ardelyx has two commercial products approved in the United States, IBSRELA®(tenapanor) and XPHOZAH®(tenapanor). The company’s pipeline includes the Phase 3 development of tenapanor for chronic idiopathic constipation (CIC) and RDX10531, a next-generation NHE3 inhibitor with potential application across multiple therapeutic areas. Ardelyx has agreements for the development and commercialization of tenapanor outside of the U.S. Kyowa Kirin commercializes PHOZEVEL®(tenapanor) for hyperphosphatemia in Japan. A New Drug Application for tenapanor for hyperphosphatemia has been approved in China with Fosun Pharma. Knight Therapeutics commercializes IBSRELA in Canada. For more information, please visithttps://ardelyx.com/and connect with us onX (formerly known as Twitter), LinkedInandFacebook.